Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.

Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Iwase H.

Cancer Biomark. 2018 Apr 7. doi: 10.3233/CBM-171161. [Epub ahead of print]

PMID:
29689710
2.

Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.

Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Murakami K, Iwase H.

Mol Cancer. 2018 Feb 26;17(1):67. doi: 10.1186/s12943-018-0808-y.

3.

Factors involved in early lenvatinib dose reduction: a retrospective analysis.

Suyama K, Tomiguchi M, Takeshita T, Sueta A, Yamamoto-Ibusuki M, Shimokawa M, Yamamoto Y, Iwase H.

Med Oncol. 2018 Jan 31;35(3):19. doi: 10.1007/s12032-018-1088-5.

PMID:
29387983
4.

Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.

Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Sueta A, Tomiguchi M, Murakami K, Omoto Y, Iwase H.

BMC Cancer. 2017 Nov 22;17(1):786. doi: 10.1186/s12885-017-3779-2.

5.

Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence.

Sueta A, Yamamoto Y, Tomiguchi M, Takeshita T, Yamamoto-Ibusuki M, Iwase H.

Oncotarget. 2017 Jul 22;8(41):69934-69944. doi: 10.18632/oncotarget.19482. eCollection 2017 Sep 19.

6.

Genetic and environmental factors and serum hormones, and risk of estrogen receptor-positive breast cancer in pre- and postmenopausal Japanese women.

Guo J, Sueta A, Nakamura K, Yoshimoto N, Baba M, Ishida N, Hagio K, Toyama T, Iwase H, Tamakoshi A, Yamashita H.

Oncotarget. 2017 Aug 11;8(39):65759-65769. doi: 10.18632/oncotarget.20182. eCollection 2017 Sep 12.

7.

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients.

Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Murakami K, Omoto Y, Iwase H.

Oncotarget. 2017 Jun 14;8(32):52142-52155. doi: 10.18632/oncotarget.18479. eCollection 2017 Aug 8.

8.

Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients.

Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Murakami K, Omoto Y, Iwase H.

Transl Oncol. 2017 Oct;10(5):766-771. doi: 10.1016/j.tranon.2017.07.004. Epub 2017 Aug 1.

9.

Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer.

Suyama K, Fujiwara S, Takeshita T, Sueta A, Inao T, Yamamoto-Ibusuki M, Yamamoto Y, Iwase H.

Mol Clin Oncol. 2017 Jul;7(1):24-26. doi: 10.3892/mco.2017.1265. Epub 2017 May 17.

10.

Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction.

Sueta D, Suyama K, Sueta A, Tabata N, Yamashita T, Tomiguchi M, Takeshita T, Yamamoto-Ibusuki M, Yamamoto E, Izumiya Y, Kaikita K, Yamamoto Y, Hokimoto S, Iwase H, Tsujita K.

Atherosclerosis. 2017 May;260:116-120. doi: 10.1016/j.atherosclerosis.2017.03.039. Epub 2017 Mar 30.

PMID:
28390289
11.

Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis.

Imamura T, Yamamoto-Ibusuki M, Sueta A, Kubo T, Irie A, Kikuchi K, Kariu T, Iwase H.

Breast Cancer. 2016 Nov;23(6):876-885. Epub 2015 Oct 22.

PMID:
26494574
12.

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.

Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, Omoto Y, Iwase H.

Oncotarget. 2016 May 31;7(22):32504-18. doi: 10.18632/oncotarget.8839.

13.

Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.

Tomiguchi M, Yamamoto Y, Yamamoto-Ibusuki M, Goto-Yamaguchi L, Fujiki Y, Fujiwara S, Sueta A, Hayashi M, Takeshita T, Inao T, Iwase H.

Cancer Sci. 2016 Apr;107(4):491-8. doi: 10.1111/cas.12897. Epub 2016 Mar 28.

14.

Associations Between Elastography Findings and Clinicopathological Factors in Breast Cancer.

Hayashi M, Yamamoto Y, Sueta A, Tomiguchi M, Yamamoto-Ibusuki M, Kawasoe T, Hamada A, Iwase H.

Medicine (Baltimore). 2015 Dec;94(50):e2290. doi: 10.1097/MD.0000000000002290.

15.

Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens.

Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, Omoto Y, Iwase H.

Transl Res. 2015 Dec;166(6):540-553.e2. doi: 10.1016/j.trsl.2015.09.003. Epub 2015 Sep 14.

PMID:
26434753
16.

Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.

Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, Omoto Y, Iwase H.

Cancer Sci. 2015 Nov;106(11):1582-9. doi: 10.1111/cas.12813. Epub 2015 Oct 30.

17.

Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy.

Omoto Y, Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Hayashi M, Sueta A, Fujiwara S, Taguchi T, Iwase H.

Springerplus. 2015 Mar 5;4:108. doi: 10.1186/s40064-015-0851-8. eCollection 2015.

18.

Differential role of MACC1 expression and its regulation of the HGF/c‑Met pathway between breast and colorectal cancer.

Sueta A, Yamamoto Y, Yamamoto-Ibusuki M, Hayashi M, Takeshita T, Yamamoto S, Omoto Y, Iwase H.

Int J Oncol. 2015 May;46(5):2143-53. doi: 10.3892/ijo.2015.2907. Epub 2015 Feb 25.

PMID:
25738887
19.

An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.

Sueta A, Yamamoto Y, Yamamoto-Ibusuki M, Hayashi M, Takeshita T, Yamamoto S, Iwase H.

PLoS One. 2014 Dec 26;9(12):e116054. doi: 10.1371/journal.pone.0116054. eCollection 2014.

20.

C6ORF97-ESR1 breast cancer susceptibility locus: influence on progression and survival in breast cancer patients.

Yamamoto-Ibusuki M, Yamamoto Y, Fujiwara S, Sueta A, Yamamoto S, Hayashi M, Tomiguchi M, Takeshita T, Iwase H.

Eur J Hum Genet. 2015 Jul;23(7):949-56. doi: 10.1038/ejhg.2014.219. Epub 2014 Nov 5.

21.

The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer.

Fujiwara S, Hung M, Yamamoto-Ibusuk CM, Yamamoto Y, Yamamoto S, Tomiguchi M, Takeshita T, Hayashi M, Sueta A, Iwase H.

Oncotarget. 2014 Jun 15;5(11):3919-30.

22.

Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?

Sueta A, Yamamoto Y, Hayashi M, Yamamoto S, Inao T, Ibusuki M, Murakami K, Iwase H.

Surgery. 2014 May;155(5):927-35. doi: 10.1016/j.surg.2014.01.009. Epub 2014 Feb 5.

PMID:
24582496
23.

Clinical significance of CYLD downregulation in breast cancer.

Hayashi M, Jono H, Shinriki S, Nakamura T, Guo J, Sueta A, Tomiguchi M, Fujiwara S, Yamamoto-Ibusuki M, Murakami K, Yamashita S, Yamamoto Y, Li JD, Iwase H, Ando Y.

Breast Cancer Res Treat. 2014 Feb;143(3):447-57. doi: 10.1007/s10549-013-2824-3. Epub 2014 Jan 8.

PMID:
24398777
24.

Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers.

French JD, Ghoussaini M, Edwards SL, Meyer KB, Michailidou K, Ahmed S, Khan S, Maranian MJ, O'Reilly M, Hillman KM, Betts JA, Carroll T, Bailey PJ, Dicks E, Beesley J, Tyrer J, Maia AT, Beck A, Knoblauch NW, Chen C, Kraft P, Barnes D, González-Neira A, Alonso MR, Herrero D, Tessier DC, Vincent D, Bacot F, Luccarini C, Baynes C, Conroy D, Dennis J, Bolla MK, Wang Q, Hopper JL, Southey MC, Schmidt MK, Broeks A, Verhoef S, Cornelissen S, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Fasching PA, Loehberg CR, Ekici AB, Beckmann MW, Peto J, dos Santos Silva I, Johnson N, Aitken Z, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Guénel P, Truong T, Laurent-Puig P, Menegaux F, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Milne RL, Zamora MP, Arias Perez JI, Benitez J, Anton-Culver H, Brenner H, Müller H, Arndt V, Stegmaier C, Meindl A, Lichtner P, Schmutzler RK, Engel C, Brauch H, Hamann U, Justenhoven C; GENICA Network, Aaltonen K, Heikkilä P, Aittomäki K, Blomqvist C, Matsuo K, Ito H, Iwata H, Sueta A, Bogdanova NV, Antonenkova NN, Dörk T, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM; kConFab Investigators, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Lambrechts D, Peeters S, Smeets A, Floris G, Chang-Claude J, Rudolph A, Nickels S, Flesch-Janys D, Radice P, Peterlongo P, Bonanni B, Sardella D, Couch FJ, Wang X, Pankratz VS, Lee A, Giles GG, Severi G, Baglietto L, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Goldberg MS, Labrèche F, Dumont M, Teo SH, Yip CH, Ng CH, Vithana EN, Kristensen V, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Devilee P, Seynaeve C, García-Closas M, Figueroa J, Chanock SJ, Lissowska J, Czene K, Klevebring D, Schoof N, Hooning MJ, Martens JW, Collée JM, Tilanus-Linthorst M, Hall P, Li J, Liu J, Humphreys K, Shu XO, Lu W, Gao YT, Cai H, Cox A, Balasubramanian SP, Blot W, Signorello LB, Cai Q, Pharoah PD, Healey CS, Shah M, Pooley KA, Kang D, Yoo KY, Noh DY, Hartman M, Miao H, Sng JH, Sim X, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Sangrajrang S, Gaborieau V, McKay J, Toland AE, Ambrosone CB, Yannoukakos D, Godwin AK, Shen CY, Hsiung CN, Wu PE, Chen ST, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, Ponder BA, Nevanlinna H, Brown MA, Chenevix-Trench G, Easton DF, Dunning AM.

Am J Hum Genet. 2013 Apr 4;92(4):489-503. doi: 10.1016/j.ajhg.2013.01.002. Epub 2013 Mar 27.

25.

Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls.

Zheng W, Zhang B, Cai Q, Sung H, Michailidou K, Shi J, Choi JY, Long J, Dennis J, Humphreys MK, Wang Q, Lu W, Gao YT, Li C, Cai H, Park SK, Yoo KY, Noh DY, Han W, Dunning AM, Benitez J, Vincent D, Bacot F, Tessier D, Kim SW, Lee MH, Lee JW, Lee JY, Xiang YB, Zheng Y, Wang W, Ji BT, Matsuo K, Ito H, Iwata H, Tanaka H, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Teo SH, Yip CH, Kang IN, Wong TY, Shen CY, Yu JC, Huang CS, Hou MF, Hartman M, Miao H, Lee SC, Putti TC, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Sangrajrang S, Shen H, Chen K, Wu PE, Ren Z, Haiman CA, Sueta A, Kim MK, Khoo US, Iwasaki M, Pharoah PD, Wen W, Hall P, Shu XO, Easton DF, Kang D.

Hum Mol Genet. 2013 Jun 15;22(12):2539-50. doi: 10.1093/hmg/ddt089. Epub 2013 Mar 27.

26.

Large-scale genotyping identifies 41 new loci associated with breast cancer risk.

Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, Wang Q, Dicks E, Lee A, Turnbull C, Rahman N; Breast and Ovarian Cancer Susceptibility Collaboration, Fletcher O, Peto J, Gibson L, Dos Santos Silva I, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Czene K, Irwanto A, Liu J, Waisfisz Q, Meijers-Heijboer H, Adank M; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), van der Luijt RB, Hein R, Dahmen N, Beckman L, Meindl A, Schmutzler RK, Müller-Myhsok B, Lichtner P, Hopper JL, Southey MC, Makalic E, Schmidt DF, Uitterlinden AG, Hofman A, Hunter DJ, Chanock SJ, Vincent D, Bacot F, Tessier DC, Canisius S, Wessels LF, Haiman CA, Shah M, Luben R, Brown J, Luccarini C, Schoof N, Humphreys K, Li J, Nordestgaard BG, Nielsen SF, Flyger H, Couch FJ, Wang X, Vachon C, Stevens KN, Lambrechts D, Moisse M, Paridaens R, Christiaens MR, Rudolph A, Nickels S, Flesch-Janys D, Johnson N, Aitken Z, Aaltonen K, Heikkinen T, Broeks A, Veer LJ, van der Schoot CE, Guénel P, Truong T, Laurent-Puig P, Menegaux F, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Zamora MP, Perez JI, Pita G, Alonso MR, Cox A, Brock IW, Cross SS, Reed MW, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Henderson BE, Schumacher F, Le Marchand L, Andrulis IL, Knight JA, Glendon G, Mulligan AM; kConFab Investigators; Australian Ovarian Cancer Study Group, Lindblom A, Margolin S, Hooning MJ, Hollestelle A, van den Ouweland AM, Jager A, Bui QM, Stone J, Dite GS, Apicella C, Tsimiklis H, Giles GG, Severi G, Baglietto L, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Müller H, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Jones M, Figueroa J, Lissowska J, Brinton L, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Brauch H, Hamann U, Brüning T; GENICA (Gene Environment Interaction and Breast Cancer in Germany) Network, Radice P, Peterlongo P, Manoukian S, Bonanni B, Devilee P, Tollenaar RA, Seynaeve C, van Asperen CJ, Jakubowska A, Lubinski J, Jaworska K, Durda K, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Bogdanova NV, Antonenkova NN, Dörk T, Kristensen VN, Anton-Culver H, Slager S, Toland AE, Edge S, Fostira F, Kang D, Yoo KY, Noh DY, Matsuo K, Ito H, Iwata H, Sueta A, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Shu XO, Lu W, Gao YT, Cai H, Teo SH, Yip CH, Phuah SY, Cornes BK, Hartman M, Miao H, Lim WY, Sng JH, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Shen CY, Hsiung CN, Wu PE, Ding SL, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Blot WJ, Signorello LB, Cai Q, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Simard J, Garcia-Closas M, Pharoah PD, Chenevix-Trench G, Dunning AM, Benitez J, Easton DF.

Nat Genet. 2013 Apr;45(4):353-61, 361e1-2. doi: 10.1038/ng.2563.

27.

Differential impact of body mass index and its change on the risk of breast cancer by molecular subtype: A case-control study in Japanese women.

Sueta A, Ito H, Islam T, Hosono S, Watanabe M, Hirose K, Fujita T, Yatabe Y, Iwata H, Tajima K, Tanaka H, Iwase H, Matsuo K.

Springerplus. 2012 Dec;1(1):39. doi: 10.1186/2193-1801-1-39. Epub 2012 Oct 23.

28.

Alcohol and dietary folate intake and the risk of breast cancer: a case-control study in Japan.

Islam T, Ito H, Sueta A, Hosono S, Hirose K, Watanabe M, Iwata H, Tajima K, Tanaka H, Matsuo K.

Eur J Cancer Prev. 2013 Jul;22(4):358-66. doi: 10.1097/CEJ.0b013e32835b6a60.

PMID:
23183091
29.

A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population.

Sueta A, Ito H, Kawase T, Hirose K, Hosono S, Yatabe Y, Tajima K, Tanaka H, Iwata H, Iwase H, Matsuo K.

Breast Cancer Res Treat. 2012 Apr;132(2):711-21. doi: 10.1007/s10549-011-1904-5. Epub 2011 Dec 11.

PMID:
22160591
30.

Stromal sarcoma of the breast with lung metastases showing a clinical complete response to doxorubicin plus ifosfamide treatment: report of a case.

Sueta A, Yamamoto Y, Inoue K, Kuriwaki K, Iwase H.

Surg Today. 2011 Aug;41(8):1145-9. doi: 10.1007/s00595-010-4406-x. Epub 2011 Jul 20.

PMID:
21773909
31.

High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers.

Horio A, Fujita T, Hayashi H, Hattori M, Kondou N, Yamada M, Adachi E, Ushio A, Gondou N, Sueta A, Yatabe Y, Iwata H.

Int J Clin Oncol. 2012 Apr;17(2):131-6. doi: 10.1007/s10147-011-0269-4. Epub 2011 Jun 18.

PMID:
21681642
32.

[A case of mammary Paget's disease with early systemic recurrence after operation].

Sueta A, Yamamoto Y, Arase K, Iizaka M, Kuriwaki K, Inoue K.

Gan To Kagaku Ryoho. 2010 Jul;37(7):1329-32. Japanese.

PMID:
20647720
33.

[A case of spindle cell carcinoma of the breast including metaplastic lesion with poor prognosis].

Nakano M, Yamamoto Y, Kawasoe T, Hayashi M, Sueta A, Honda Y, Iyama K, Iwase H.

Gan To Kagaku Ryoho. 2009 Jun;36(6):1017-9. Japanese.

PMID:
19542728
34.

Asthma mortality in Uruguay, 1984-1998.

Baluga JC, Sueta A, Ceni M.

Ann Allergy Asthma Immunol. 2001 Aug;87(2):124-8.

PMID:
11527243

Supplemental Content

Support Center